UBS analyst Trung Huynh lowered the firm’s price target on Insmed (INSM) to $109 from $110 and keeps a Buy rating on the shares. Insmed’s print was straightforward, with building anticipation into a catalyst-rich period, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed Reports Strong Q1 2025 Growth and Progress
- Insmed’s Promising Pipeline and Strong Financials Justify Buy Rating
- Insmed’s Strategic Growth and Pipeline Progress Drive Buy Rating
- Insmed’s Promising Future: Buy Rating Backed by Brensocatib Launch and Strong Clinical Pipeline
- Insmed’s Earnings Call: Strong Growth and Optimistic Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue